Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marsh & McLennan Companies, Inc. (MRSH) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Marsh & McLennan Companies, Inc.Trade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Marsh & McLennan Companies, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.94 (market cap $84.31B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 48.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and DENTSPLY SIRONA Inc for 72 Days on average.

MRSHXRAY
Market Cap
$84.31B$1.73B
Volume
3,948,9476,198,582
Sector
FinancialsHealth
52-Week High
$207.02$14.68
52-Week Low
$157.32$8.52
Typical Hold Time
109 Days72 Days
Enterprise Value
$104.99B$3.80B
Dividend Yield
2.24%5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marsh & McLennan Companies, Inc.

MRSH trades at $176.16, up 1.44% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company completed the acquisition of Accel Holdings on October 2, 2026, expanding its advisory footprint. Revenue grew to $27.0B in 2025, with a net income margin of 15.41%, while valuation ratios like P/E of 21.57 and ROE of 25.72% reflect strong profitability. Analysts maintain a consensus price target of $202.71, though sentiment is mixed with a 'Hold' rating from most.

The outlook for MRSH is positive due to earnings momentum and strategic acquisitions, but risks include competitive pressures and potential margin compression. Upside remains if the company meets Q3 2026 EPS expectations of $1.97, supported by solid cash flow trends. Investors should weigh the high P/B ratio of 5.55 against growth prospects in the reinsurance sector.

DENTSPLY SIRONA Inc

Dentsply Sirona (XRAY) trades at $8.73, near its 52-week low, with a bearish technical signal and negative profitability metrics. The company reported a Q2 2026 earnings beat but faces declining revenue and negative net income margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid a challenging dental market environment.

The outlook remains cautious due to persistent margin pressure and sales declines, though the consensus price target of $13.40 suggests potential upside. Key risks include competitive pressures and execution of the turnaround plan, while institutional buying indicates some long-term confidence.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRSH
100% Buy0% Sell
Avg holding period · 109 Days
XRAY

No sentiment data available yet.

About Marsh & McLennan Companies, Inc.

Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).

Read more on MRSH →

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY →